Identification of PE risk early in a pregnancy and accurate diagnosis could help to decrease the incidence of maternal and fetal complications. Recently, several new and promising biomarkers have been studied for their ability to predict PE in high-risk pregnancies. Identification of the disorder at an early stage may allow for earlier patient treatment and improved outcomes for both the mother and baby. The availability of such biomarkers could have a significant impact on the medical management of pregnant women with PE. Moreover, the availability of reliable biomarkers may help to confirm the clinical diagnosis of PE.
Based on the current understanding of the pathophysiology of PE, much research has revolved around the identification of placental factors that show abnormal expression in preeclamptic placentas. These factors may be useful as non-invasive early predictors or detectors of the disorder
Note: One such promising biomarker test system has been given FDA-approval in May 2023. Details of this biomarker test system are presented in another section.
